close

Agreements

Date: 2010-01-10

Type of information: Nomination

Compound:

Company: Bind Biosciences (USA - MA)

Therapeutic area:

Type agreement:

nomination

Action mechanism:

Disease:

Details:

* On January 11, 2010, Bind Biosciences announced the appointment of Scott Minick as President and CEO. Mr. Minick was formerly a Managing Director at ARCH Venture Partners, a major BIND investor, and previously the President and COO of Sequus Pharmaceuticals/Liposome Technology Inc., where he led the company during its 1995 FDA approval and successful commercial launch of the leading oncology drug, Doxil® (liposomal doxorubicin). Sequus was subsequently acquired by Alza for $580 MM.

 

Financial terms:

Latest news:

Is general: Yes